Akari Therapeutics (AKTX) Accumulated Depreciation & Amortization (2011 - 2020)
Akari Therapeutics recorded quarterly Accumulated Depreciation & Amortization of $164938.0 in Q4 2020, up 1.29% quarter-over-quarter from $162842.0 in Q1 2020, and up 3393.49% year-over-year from $4721.3 in Q1 2020.
Akari Therapeutics' Accumulated Depreciation & Amortization history runs 10 years deep, the most recent figure standing at $164938.0 for Q4 2020.
- In Q4 2020, Accumulated Depreciation & Amortization rose 3393.49% year-over-year to $164938.0; the TTM figure through Dec 2020 stood at $164938.0 (up 3393.49% YoY), while the FY2020 annual figure was $164938.0, up 3393.49% from the prior year.
- Accumulated Depreciation & Amortization came in at $164938.0 for Q4 2020 at Akari Therapeutics, up from $162842.0 in the prior quarter.
- In the past five years, Accumulated Depreciation & Amortization ranged from a high of $164938.0 in Q4 2020 to a low of -$58306.0 in Q4 2016.
- A 5-year average of $31369.8 and a median of -$12706.5 in 2018 frame the typical range for Accumulated Depreciation & Amortization.
- Across the five-year window, Accumulated Depreciation & Amortization sank 44.07% in 2016 and jumped 3393.49% in 2020, its largest moves.
- Akari Therapeutics' Accumulated Depreciation & Amortization stood at -$58306.0 in 2016, then advanced by 4.23% to -$55842.0 in 2017, then jumped by 63.46% to -$20405.0 in 2018, then soared by 75.46% to -$5008.0 in 2019, then surged by 3393.49% to $164938.0 in 2020.
- According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $164938.0, $162842.0, and -$5008.0 for Q4 2020, Q1 2020, and Q4 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 164,938.00 |
| Dec 31, 2020 | 164,938.00 |
| Mar 31, 2020 | 162,842.00 |
| Mar 31, 2020 | 162,842.00 |
| Dec 31, 2019 | -5,008.00 |
| Dec 31, 2019 | -5,008.00 |
| Dec 31, 2018 | -20,405.00 |
| Dec 31, 2018 | -20,405.00 |
| Dec 31, 2017 | -55,842.00 |
| Dec 31, 2017 | -55,842.00 |
| Dec 31, 2016 | -58,306.00 |
| Dec 31, 2016 | -58,306.00 |
| Dec 31, 2015 | -40,472.00 |
| Dec 31, 2015 | -40,472.00 |
| Dec 31, 2014 | 67,000.00 |
| Dec 31, 2014 | 67,000.00 |
| Dec 31, 2013 | 10,000.00 |
| Dec 31, 2013 | 10,000.00 |
| Dec 31, 2012 | 11,000.00 |
| Dec 31, 2012 | 11,000.00 |
| Dec 31, 2011 | 9,000.00 |
| Dec 31, 2011 | 9,000.00 |